Cargando…
Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay
Despite efforts to develop anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody (Ab) immunoassays, reliable serological methods are still needed. We developed a multiplex addressable laser bead immunoassay (ALBIA) to detect and quantify anti-Spike S1 and nucleocapsid N Abs. Rec...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726470/ https://www.ncbi.nlm.nih.gov/pubmed/33324387 http://dx.doi.org/10.3389/fmicb.2020.603931 |
_version_ | 1783620895542083584 |
---|---|
author | Drouot, Laurent Hantz, Sébastien Jouen, Fabienne Velay, Aurélie Lamia, Bouchra Veber, Benoit Sibilia, Jean Lotellier, Marlène Candon, Sophie Alain, Sophie Fafi-Kremer, Samira Boyer, Olivier |
author_facet | Drouot, Laurent Hantz, Sébastien Jouen, Fabienne Velay, Aurélie Lamia, Bouchra Veber, Benoit Sibilia, Jean Lotellier, Marlène Candon, Sophie Alain, Sophie Fafi-Kremer, Samira Boyer, Olivier |
author_sort | Drouot, Laurent |
collection | PubMed |
description | Despite efforts to develop anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody (Ab) immunoassays, reliable serological methods are still needed. We developed a multiplex addressable laser bead immunoassay (ALBIA) to detect and quantify anti-Spike S1 and nucleocapsid N Abs. Recombinant S1 and N proteins were bound to fluorescent beads (ALBIA-IgG-S1/N). Abs were revealed using class-specific anti-human Ig Abs. The performances of the test were analyzed on 575 serum samples including 192 from SARS-CoV-2 polymerase chain reaction–confirmed patients, 13 from seasonal coronaviruses, 70 from different inflammatory/autoimmune diseases, and 300 from healthy donors. Anti-S1 IgM were detected by monoplex ALBIA-IgM-S1. Comparison with chemiluminescent assays or enzyme-linked immunosorbent assays was performed using commercial tests. Multiplex ALBIA-IgG-S1/N was effective in detecting and quantifying anti–SARS-CoV-2 IgG Abs. Two weeks after first symptoms, sensitivity and specificity were 97.7 and 98.0% (anti-S1), and 100 and 98.7% (anti-N), respectively. Agreement with commercial tests was good to excellent, with a higher sensitivity of ALBIA. ALBIA-IgG-S1/N was positive in 53% of patients up to day 7, and in 75% between days 7 and 13. For ALBIA-IgM-S1, sensitivity and specificity were 74.4 and 98.7%, respectively. Patients in intensive care units had higher IgG Ab levels (Mann–Whitney test, p < 0.05). ALBIA provides a robust method for exploring humoral immunity to SARS-CoV-2. Serology should be performed after 2 weeks following first symptoms, when all COVID-19 (coronavirus disease 2019) patients had at least one anti-S1 or anti-N IgG Ab, illustrating the interest of a multiplex test. |
format | Online Article Text |
id | pubmed-7726470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77264702020-12-14 Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay Drouot, Laurent Hantz, Sébastien Jouen, Fabienne Velay, Aurélie Lamia, Bouchra Veber, Benoit Sibilia, Jean Lotellier, Marlène Candon, Sophie Alain, Sophie Fafi-Kremer, Samira Boyer, Olivier Front Microbiol Microbiology Despite efforts to develop anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody (Ab) immunoassays, reliable serological methods are still needed. We developed a multiplex addressable laser bead immunoassay (ALBIA) to detect and quantify anti-Spike S1 and nucleocapsid N Abs. Recombinant S1 and N proteins were bound to fluorescent beads (ALBIA-IgG-S1/N). Abs were revealed using class-specific anti-human Ig Abs. The performances of the test were analyzed on 575 serum samples including 192 from SARS-CoV-2 polymerase chain reaction–confirmed patients, 13 from seasonal coronaviruses, 70 from different inflammatory/autoimmune diseases, and 300 from healthy donors. Anti-S1 IgM were detected by monoplex ALBIA-IgM-S1. Comparison with chemiluminescent assays or enzyme-linked immunosorbent assays was performed using commercial tests. Multiplex ALBIA-IgG-S1/N was effective in detecting and quantifying anti–SARS-CoV-2 IgG Abs. Two weeks after first symptoms, sensitivity and specificity were 97.7 and 98.0% (anti-S1), and 100 and 98.7% (anti-N), respectively. Agreement with commercial tests was good to excellent, with a higher sensitivity of ALBIA. ALBIA-IgG-S1/N was positive in 53% of patients up to day 7, and in 75% between days 7 and 13. For ALBIA-IgM-S1, sensitivity and specificity were 74.4 and 98.7%, respectively. Patients in intensive care units had higher IgG Ab levels (Mann–Whitney test, p < 0.05). ALBIA provides a robust method for exploring humoral immunity to SARS-CoV-2. Serology should be performed after 2 weeks following first symptoms, when all COVID-19 (coronavirus disease 2019) patients had at least one anti-S1 or anti-N IgG Ab, illustrating the interest of a multiplex test. Frontiers Media S.A. 2020-11-26 /pmc/articles/PMC7726470/ /pubmed/33324387 http://dx.doi.org/10.3389/fmicb.2020.603931 Text en Copyright © 2020 Drouot, Hantz, Jouen, Velay, Lamia, Veber, Sibilia, Lotellier, Candon, Alain, Fafi-Kremer and Boyer. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Drouot, Laurent Hantz, Sébastien Jouen, Fabienne Velay, Aurélie Lamia, Bouchra Veber, Benoit Sibilia, Jean Lotellier, Marlène Candon, Sophie Alain, Sophie Fafi-Kremer, Samira Boyer, Olivier Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay |
title | Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay |
title_full | Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay |
title_fullStr | Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay |
title_full_unstemmed | Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay |
title_short | Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay |
title_sort | evaluation of humoral immunity to sars-cov-2: diagnostic value of a new multiplex addressable laser bead immunoassay |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726470/ https://www.ncbi.nlm.nih.gov/pubmed/33324387 http://dx.doi.org/10.3389/fmicb.2020.603931 |
work_keys_str_mv | AT drouotlaurent evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT hantzsebastien evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT jouenfabienne evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT velayaurelie evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT lamiabouchra evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT veberbenoit evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT sibiliajean evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT lotelliermarlene evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT candonsophie evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT alainsophie evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT fafikremersamira evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay AT boyerolivier evaluationofhumoralimmunitytosarscov2diagnosticvalueofanewmultiplexaddressablelaserbeadimmunoassay |